Finceramica was established in 1987 at the initiative of a few researchers who decided to bring to life a company based on innovative ideas in the medical field. In 1992, realizing the potential of Finceramica, Tampieri took it over as a spin-off of the Institute for Science and Technology for Ceramics of the National Research Council (CNR). Over the years it brought forward an important investment plan to launch a new phase of company growth. The work carried out at Finceramica lies at the junction between the thousand-year old evolution of ceramic processes and innovation in biomaterials, biosciences and "regenerative surgery".

Today Finceramica is a company that develops, manufactures and markets ground-breaking ceramic biomaterials and ceramic-polymeric compounds especially for three medical areas: orthopaedic surgery, neurosurgery and maxillofacial surgery.

Finceramica focuses primarily on the study and creation of "custom-made" biomedical solutions aimed at solving specific medical problems encountered daily in operating theatres. Research activities are encoded in the DNA of Finceramica and intend to contribute concretely to both present and future biomedical progress. Finceramica's technology platform, whether it deals with innovative ceramic materials or biotechnologies, revolves around the human being and the specific needs of patients and surgeons. The innovative technologies developed by Finceramica in collaboration with internationally renowned research institutes have paved the way to new generations of biomaterials able to interact with and integrate in the human body, and eventually regenerate damaged bone tissues.

One of the materials Finceramica is investigating most closely is hydroxyapatite, the mineral which makes up 70% of the human bone. Once implanted, new generation hydroxyapatite-based biomaterials form an ideal micro-environment to biologically support the development of the new bone.

At the end of 2016 CustomizedBone Service, which is how the well-known CustomBone Service is trademarked on the American market, obtained the US product marketing authorization issued by the strict Food and Drug Administration (FDA). This approval followed the submission of a "510k" file, aimed at proving substantial equivalence of the Italian device to at least another (predicate) device already legally marketed in the US, hence, already FDA approved. The dossier must be complete with, among other things, product details, comparative tests, and clinical data. The time required for approval generally depends on the complexity of the case and on how equivalent the compared devices actually are. CustomizedBone was a particular case, as this is the only FDA approved porous hydroxyapatite device for this type of therapeutic indication.

Vittoria Graziani
Presso office of Finceramica and Tampieri Group manager

mob +39 345 6702347
t +39 0546 607311
pressoffice@finceramica.it
www.finceramica.it